A higher cytotoxic effect has been shown in glioblastoma cells with the use of a combined therapy with PDGFR and VEGFR inhibitors or a dual targeting pathway compared to a single treatment (Purcaru et al., 2015). The gene discussed is PDGFRB; the disease is glioblastoma.